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PREDICTIVE VALUE OF LOW FERRITIN IN OLDER
PERSONS WITH ANEMIA WITH AND WITHOUT
INFLAMMATION: THE LEIDEN 85-PLUS STUDY
To the Editor: Iron deficiency is a common cause of anemia,
being found in more than 15% of older persons with ane-
mia.1,2 Serum ferritin levels strongly correlate with body
iron stores3 and are considered the best noninvasive test for
the diagnosis of iron deficiency.2,4 Ferritin therefore plays a
central role in diagnostic and therapeutic algorithms for
iron deficiency anemia in clinical practice,5 although ferri-
tin is also an acute-phase protein and may be high with
acute and chronic inflammatory conditions such as infec-
tions, rheumatoid arthritis, and cancer.2 Because the prev-
alence of inflammatory conditions is very high in old age,6 it
is not clear whether low ferritin can be used as a marker of
low iron status in old age. Therefore, the association be-
tween low ferritin levels and anemia in old age in the pres-
ence and absence of inflammation was investigated.
METHODS
The present study is embedded in the Leiden 85-plus Study,
a population-based prospective follow-up study of 512 85-
year-old inhabitants of Leiden, the Netherlands.7 Partici-
pants who used iron supplements were excluded from the
present study. At age 85, ferritin levels were determined
using an immunological assay (E170, Roche, Almere, the
Netherlands). Low serum ferritin was defined as ferritin less
than 20mg/L for men and less than 15mg/L for women.8
C-reactive protein (CRP) levels were measured using a
Hitachi 747 automated analyzer (Hitachi, Tokyo, Japan).
High CRP was defined as CRP greater than 5 mg/L. He-
moglobin levels and mean corpuscular volume (MCV) were
determined annually (aged 85–90) using an automated
analysis system (Coulter Counter, Coulter Electronics, Hi-
aleah, FL). Anemia was defined according to criteria of the
World Health Organization (hemoglobin o130 g/L for
men and o120 g/L for women).9
RESULTS
One hundred seventy-eight participants (34.8%) were
male. The prevalence of anemia was 23.8% (n 5 122); 35
participants (6.8%) had low ferritin levels. Participants
with low ferritin levels had more than twice the risk of
having anemia than participants with normal ferritin levels
(odds ratio (OR) 5 2.2, 95% CI 5 1.1–4.5). In participants
with high CRP levels (n 5 171), low ferritin was associated
with a risk of anemia that was 7 times as great (OR 7.0,
95% CI 5 1.4–34.9). No significant association was found
between low ferritin and anemia in participants with nor-
mal CRP levels (n 5 341, OR 1.7, 95% CI 5 0.7–4.2).
The lowest hemoglobin levels were found in partici-
pants with low ferritin and high CRP levels (mean (SE)
hemoglobin level 99 g/L (11 g/L) in men and 112 g/L (8 g/L)
in women, Figure 1). Similar results were found for MCV
(data not shown). Low ferritin was also associated with an
additional decline in hemoglobin level (additional annual
change in hemoglobin  2 g/L, 95% CI 5 4.0 to 0.3 g/
L) and MCV (additional annual change in MCV  0.78 fL,
95% CI 5  1.3 to  0.22 fL) in the years thereafter.
Again, these associations were most apparent in partici-
pants with high CRP levels. In this subgroup, low ferritin
was associated with an additional annual decline in hemo-
globin level of 5 g/L (additional annual change in hemo-
globin level 5 g/L, 95% CI 5  10 to 0.4 g/L) and an
additional annual decline in MCV of 2.2 fL (additional
annual change in MCV 2.2 fL, 95% CI 5  3.6 to
 0.71 fL).
DISCUSSION
The present study shows that low ferritin is associated with
anemia in old age. This association is most prominent in
older individuals with signs of an inflammatory host re-
sponse in the plasma.
The diagnostic value of serum ferritin levels to detect
iron deficiency in patients with anemia, infection, and in-
flammation has been questioned because of ferritin’s ‘‘acute
phase’’ properties. The findings presented here show the
significance of measuring ferritin levels in older individuals,
especially in those with infection or inflammation. In these
patients, a low level of ferritin is a specific marker of iron
status because of its ‘‘acute phase’’ properties; iron status
must be poor when low ferritin levels are found in the
presence of systemic inflammation.
How can the occurrence of low ferritin levels in the
presence of inflammation be explained? Older patients with
gastrointestinal tumors or chronic inflammatory diseases
will have low iron stores because of gastrointestinal blood
loss, malnutrition, or malabsorption of food-bound iron. In
these individuals, iron stores may have become too low to
facilitate a rise in ferritin in response to inflammation. Up-
regulation of hepcidinFthe main regulator of iron homeo-
stasisFis an alternative molecular pathway to explain
these findings. Proinflammatory cytokines, particularly in-
terleukin 6, induce the production and secretion of hepcidin
by hepatocytes. Hepcidin binds to the membrane protein
ferroprotein and induces its internalization and degradation
in lysosomes, blocking the export of iron from cells.10 Al-
though a preliminary analysis in the Invecchiare in Chianti
Study could not demonstrate higher urinary hepcidin levels
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in older individuals with anemia of inflammation,11 the
hypothesis should be tested in other population-based stud-
ies, preferably using serum hepcidin assays, which have re-
cently become available.12
Wendy P.J. den Elzen, MSc
Jacobijn Gussekloo, MD, PhD
Department of Public Health and Primary Care
Leiden University Medical Center
Leiden, the Netherlands
Jorien M. Willems, MD
Anton J.M. de Craen, PhD
Gerard J. Blauw, MD, PhD
Department of Gerontology and Geriatrics
Leiden University Medical Center
Leiden, the Netherlands
Gerard J. Blauw, MD, PhD
Department of Internal Medicine, Bronovo Hospital, The
Hague, the Netherlands
Willem J.J. Assendelft, MD, PhD
Department of Public Health and Primary Care
Leiden University Medical Center
Leiden, the Netherlands
Rudi G.J. Westendorp, MD, PhD
Department of Gerontology and Geriatrics
Leiden University Medical Center
Leiden, the Netherlands
Netherlands Consortium for Healthy Ageing
Leiden, the Netherlands
ACKNOWLEDGMENTS
Conflicts of interest: The editor in chief has reviewed the
conflict of interest checklist provided by the authors and has
determined that the authors have no financial or any other
kind of personal conflicts with this paper.
The Leiden 85-plus Study was partly funded by an un-
restricted grant from the Dutch Ministry of Health, Welfare
and Sports. The Leiden 85-plus Study is a collaborative
project of the Department of Gerontology and Geriatrics
(RGJ Westendorp) and the Department of Public Health
and Primary Care (J Gussekloo) of the Leiden University
Medical Center, Leiden, the Netherlands.
Author Contributions: Professor Westendorp had full
access to all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data
analysis. Study concept and design: J. Gussekloo and R.G.J.
Westendorp. Acquisition of data: J. Gussekloo, A.J.M. de
Craen, G.J. Blauw, and R.G.J. Westendorp. Analysis and
interpretation of data: W.P.J. den Elzen, J. Gussekloo, J.M.
Willems, A.J.M. de Craen, G.J. Blauw, W.J.J. Assendelft, and
R.G.J. Westendorp. Drafting of the manuscript: W.P.J. den
Elzen, J. Gussekloo, and R.G.J. Westendorp. Critical revision
of the manuscript for important intellectual content: W.P.J.
den Elzen, J. Gussekloo, J.M. Willems, A.J.M. de Craen, G.J.
Blauw, W.J.J. Assendelft, and R.G.J. Westendorp. Statistical
analysis: W.P.J. den Elzen., J. Gussekloo, A.J.M. de Craen,
and R.G.J. Westendorp. Obtained funding: J. Gussekloo and
R.G.J. Westendorp. Administrative, technical, or material
support: W.P.J. den Elzen, J. Gussekloo, A.J.M. de Craen,
and G.J. Blauw. Study supervision: J. Gussekloo, A.J.M. de
Craen, W.J.J. Assendelft, and R.G.J. Westendorp.
Sponsor’s Role: The sponsor had no role in the design,
methods, subject recruitment, data collections, analysis, or
preparation of the letter.
REFERENCES
1. Guralnik JM, Eisenstaedt RS, Ferrucci L et al. Prevalence of anemia in persons
65 years and older in the United States: Evidence for a high rate of unexplained
anemia. Blood 2004;104:2263–2268.
2. Guyatt GH, Patterson C, Ali M et al. Diagnosis of iron-deficiency anemia in the
elderly. Am J Med 1990;88:205–209.
3. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron
stores in normal subjects. J Clin Pathol 1973;26:770–772.
4. Guyatt GH, Oxman AD, Ali M et al. Laboratory diagnosis of iron-deficiency
anemia: An overview. J Gen Intern Med 1992;7:145–153.
5. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Phy-
sician 2007;75:671–678.
6. Marengoni A, Winblad B, Karp A et al. Prevalence of chronic diseases and
multimorbidity among the elderly population in Sweden. Am J Public Health
2008;98:1198–1200.
7. der Wiel AB, van Exel E, de Craen AJ et al. A high response is not essential to
prevent selection bias: Results from the Leiden 85-plus study. J Clin Epidemiol
2002;55:1119–1125.
8. Ferritine. Online SAN-memoboek voor diagnostiek in de eerste lijn [Online]
Available at http://memoboek.dynapaper.nl/33/ferritine.html Accessed June 20,
2009.
9. Nutritional anaemias. Report of a WHO scientific group. World Health Organ
Tech Rep Ser 1968;405:5–37.
Figure 1. Mean hemoglobin levels according to ferritin status and C-reactive protein (CRP) status for men and women at age 85. Low ferritin
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EVALUATION OF SHORT-TERM EFFECTIVENESS OF
THE DISEASE MANAGEMENT PROGRAM
‘‘DI.PRO.DI.’’ ON CONTINUITY OF CARE OF
PATIENTS WITH CONGESTIVE HEART FAILURE
To the Editor: This study aimed to assess the early effec-
tiveness of a disease management program (DMP), called
‘‘Dimissione Protetta Difficile’’ (Di.Pro.Di) conducted by
personnel from the intensive care unit (ICU) of Public Hos-
pital S. Paolo, Naples, Italy. This hospital serves an area of
31 km2 with 211,000 inhabitants (20.6% aged  65). This
controlled nonrandomized trial aimed to stabilize patients
fully with three home visits in the 3 months after discharge.
Rehospitalizations and hospital length of stay of elderly
patients suffering from congestive heart failure (CHF) after
discharge from the ICU were focused on, because reducing
these outcomes is a crucial challenge for developed coun-
tries because of their increasing elderly population. The lit-
erature shows that DMPs improve care.1–3 Comparing
these outcomes in treatment and control groups, using con-
ventional statistic tests, it was observed, albeit in small
numbers, that Di.Pro.Di significantly reduces the number
and risk of rehospitalizations and total hospital length of
stay.
METHODS
Multidisciplinary teams evaluate patients and educate their
families. Patients receive up to three domiciliary visits in the
3 months after discharge. Telephone communication inte-
grates these visits. A physician evaluates the patient’s con-
dition and, if there is mild deterioration, modulates the
therapy or orders further investigations. If there is major
deterioration, the patient is rehospitalized. If the patient’s
health condition is stable, the patient is fully discharged.4
The group of patients enrolled in the program (treatment
group, TG) were benchmarked with a group of patients
hospitalized in the same structure but not enrolled in the
program (control group, CG). The outcomes of a subset of
patients enrolled in the TG were retrospectively analyzed. A
t-test and a chi-square test with Yates’s correction were
performed to assess the statistical significance of the results
and the homogeneity between groups.
Protocol
Two hundred fifty patients were involved in the Di.Pro.Di,
approximately 20 at any one time. Sixteen patients met the
inclusion criteria: aged 65 and older, New York Heart As-
sociation classification II or III, high risk of rehospitaliza-
tion, and adequate family support.
The hospital provides the required predosed drugs.
During each visit, a gerontologist or cardiologist and a
nurse, supported by a car driver or orderly, perform and
electrocardiogram, oximetry, blood-gas analysis, capillary
blood glucose, and urinalysis.
Oxygen therapy or pulmonary ventilation might also
be required. After the third visit, the patient is discharged
from the Di.Pro.Di and, according to the stability criteria,
rehospitalized or transferred to local health services.
RESULTS
The results of this study are summarized in Table 1.
Outcomes
TG After Di.Pro.Di
The TG included 16 patients with a mean age of 81.0  8.8.
Four patients (25%) were rehospitalized, for a total of four
rehospitalizations, (mean 0.3, maximum of one per pa-
tient). The total hospital length of stay was 17 days (mean
total 1.1  2.1 days per patient).
TG Before Di.Pro.Di
Six patients in the TG were investigated retrospectively for
the year before the Di.Pro.Di. Five of them (83%) were
rehospitalized, for a total of 11 rehospitalizations (mean 1.8
hospitalizations; maximum 4 per patient). Total hospital
length of stay for these patients was 69 days (mean total
11.5  7.2 days per patient).
Control Group
The CG included 18 patients with a mean age of 79.5  9.6.
Eleven (61.1%) were rehospitalized, for a total of 17 re-
hospitalizations (mean 0.9, maximum 3 per patient). Total
hospital length of stay was 234 days (mean total 13.0  7.7
days per patient).
Homogeneity of TG and CG
No statistically significant difference was observed between
the CG and TG before Di.Pro.Di in terms of mean age,
number of rehospitalizations, and hospital length of stay. In
both groups, the number of rehospitalizations and hospital
lengths of stay were slightly higher than reported in previ-
ous studies,5,6 possibly because the mean age was slightly
higher.
Table 1. Rehospitalizations and Hospital Length of Stay













Patients rehospitalized 11 5 4
Rehospitalizations 17 11 4
Length of hospital stay




13.0  7.7 11.5  7.2 1.1  2.1
Disease management program ‘‘Dimissione Protetta Difficile’’ (Di.Pro.Di).
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